Small molecules inhibit ex vivo tumor growth in bone

Donghui Zhou, Khuchtumur Bum-Erdene, David Xu, Degang Liu, Doug Tompkins, Rania S. Sulaiman, Timothy Corson, John Chirgwin, Samy Meroueh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Bone is a common site of metastasis for breast, prostate, lung, kidney and other cancers. Bone metastases are incurable, and substantially reduce patient quality of life. To date, there exists no small-molecule therapeutic agent that can reduce tumor burden in bone. This is partly attributed to the lack of suitable in vitro assays that are good models of tumor growth in bone. Here, we take advantage of a novel ex vivo model of bone colonization to report a series of pyrrolopyrazolone small molecules that inhibit cancer cell invasion and ex vivo tumor growth in bone at single-digit micromolar concentration. We find that the compounds modulated the expression levels of genes associated with bone-forming osteoblasts, bone-destroying osteoclasts, cancer cell viability and metastasis. Our compounds provide chemical tools to uncover novel targets and pathways associated with bone metastasis, as well as for the development of compounds to prevent and reverse bone tumor growth in vivo.

Original languageEnglish (US)
Pages (from-to)6128-6134
Number of pages7
JournalBioorganic and Medicinal Chemistry
Volume26
Issue number23-24
DOIs
StatePublished - Dec 15 2018

Fingerprint

Bone Development
Tumors
Bone
Bone and Bones
Molecules
Neoplasms
Neoplasm Metastasis
Kidney Neoplasms
Osteoclasts
Cells
Tumor Burden
Osteoblasts
Prostate
Chemical compounds
Cell Survival
Breast
Quality of Life
Gene Expression
Lung
Assays

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Zhou, D., Bum-Erdene, K., Xu, D., Liu, D., Tompkins, D., Sulaiman, R. S., ... Meroueh, S. (2018). Small molecules inhibit ex vivo tumor growth in bone. Bioorganic and Medicinal Chemistry, 26(23-24), 6128-6134. https://doi.org/10.1016/j.bmc.2018.11.025

Small molecules inhibit ex vivo tumor growth in bone. / Zhou, Donghui; Bum-Erdene, Khuchtumur; Xu, David; Liu, Degang; Tompkins, Doug; Sulaiman, Rania S.; Corson, Timothy; Chirgwin, John; Meroueh, Samy.

In: Bioorganic and Medicinal Chemistry, Vol. 26, No. 23-24, 15.12.2018, p. 6128-6134.

Research output: Contribution to journalArticle

Zhou, D, Bum-Erdene, K, Xu, D, Liu, D, Tompkins, D, Sulaiman, RS, Corson, T, Chirgwin, J & Meroueh, S 2018, 'Small molecules inhibit ex vivo tumor growth in bone', Bioorganic and Medicinal Chemistry, vol. 26, no. 23-24, pp. 6128-6134. https://doi.org/10.1016/j.bmc.2018.11.025
Zhou D, Bum-Erdene K, Xu D, Liu D, Tompkins D, Sulaiman RS et al. Small molecules inhibit ex vivo tumor growth in bone. Bioorganic and Medicinal Chemistry. 2018 Dec 15;26(23-24):6128-6134. https://doi.org/10.1016/j.bmc.2018.11.025
Zhou, Donghui ; Bum-Erdene, Khuchtumur ; Xu, David ; Liu, Degang ; Tompkins, Doug ; Sulaiman, Rania S. ; Corson, Timothy ; Chirgwin, John ; Meroueh, Samy. / Small molecules inhibit ex vivo tumor growth in bone. In: Bioorganic and Medicinal Chemistry. 2018 ; Vol. 26, No. 23-24. pp. 6128-6134.
@article{2d0b01c4dd7e4a6a88df35b5bfed609f,
title = "Small molecules inhibit ex vivo tumor growth in bone",
abstract = "Bone is a common site of metastasis for breast, prostate, lung, kidney and other cancers. Bone metastases are incurable, and substantially reduce patient quality of life. To date, there exists no small-molecule therapeutic agent that can reduce tumor burden in bone. This is partly attributed to the lack of suitable in vitro assays that are good models of tumor growth in bone. Here, we take advantage of a novel ex vivo model of bone colonization to report a series of pyrrolopyrazolone small molecules that inhibit cancer cell invasion and ex vivo tumor growth in bone at single-digit micromolar concentration. We find that the compounds modulated the expression levels of genes associated with bone-forming osteoblasts, bone-destroying osteoclasts, cancer cell viability and metastasis. Our compounds provide chemical tools to uncover novel targets and pathways associated with bone metastasis, as well as for the development of compounds to prevent and reverse bone tumor growth in vivo.",
author = "Donghui Zhou and Khuchtumur Bum-Erdene and David Xu and Degang Liu and Doug Tompkins and Sulaiman, {Rania S.} and Timothy Corson and John Chirgwin and Samy Meroueh",
year = "2018",
month = "12",
day = "15",
doi = "10.1016/j.bmc.2018.11.025",
language = "English (US)",
volume = "26",
pages = "6128--6134",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "23-24",

}

TY - JOUR

T1 - Small molecules inhibit ex vivo tumor growth in bone

AU - Zhou, Donghui

AU - Bum-Erdene, Khuchtumur

AU - Xu, David

AU - Liu, Degang

AU - Tompkins, Doug

AU - Sulaiman, Rania S.

AU - Corson, Timothy

AU - Chirgwin, John

AU - Meroueh, Samy

PY - 2018/12/15

Y1 - 2018/12/15

N2 - Bone is a common site of metastasis for breast, prostate, lung, kidney and other cancers. Bone metastases are incurable, and substantially reduce patient quality of life. To date, there exists no small-molecule therapeutic agent that can reduce tumor burden in bone. This is partly attributed to the lack of suitable in vitro assays that are good models of tumor growth in bone. Here, we take advantage of a novel ex vivo model of bone colonization to report a series of pyrrolopyrazolone small molecules that inhibit cancer cell invasion and ex vivo tumor growth in bone at single-digit micromolar concentration. We find that the compounds modulated the expression levels of genes associated with bone-forming osteoblasts, bone-destroying osteoclasts, cancer cell viability and metastasis. Our compounds provide chemical tools to uncover novel targets and pathways associated with bone metastasis, as well as for the development of compounds to prevent and reverse bone tumor growth in vivo.

AB - Bone is a common site of metastasis for breast, prostate, lung, kidney and other cancers. Bone metastases are incurable, and substantially reduce patient quality of life. To date, there exists no small-molecule therapeutic agent that can reduce tumor burden in bone. This is partly attributed to the lack of suitable in vitro assays that are good models of tumor growth in bone. Here, we take advantage of a novel ex vivo model of bone colonization to report a series of pyrrolopyrazolone small molecules that inhibit cancer cell invasion and ex vivo tumor growth in bone at single-digit micromolar concentration. We find that the compounds modulated the expression levels of genes associated with bone-forming osteoblasts, bone-destroying osteoclasts, cancer cell viability and metastasis. Our compounds provide chemical tools to uncover novel targets and pathways associated with bone metastasis, as well as for the development of compounds to prevent and reverse bone tumor growth in vivo.

UR - http://www.scopus.com/inward/record.url?scp=85057010028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057010028&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2018.11.025

DO - 10.1016/j.bmc.2018.11.025

M3 - Article

C2 - 30470597

AN - SCOPUS:85057010028

VL - 26

SP - 6128

EP - 6134

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 23-24

ER -